Do analysts rate XLO or DYAI?

Dyadic International has a consensus price target of $3.00, suggesting a potential upside of 589.34%. Given Dyadic International's stronger consensus rating and higher probable upside, analysts clearly believe Dyadic International is more favorable than Xilio Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dyadic International 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to XLO or DYAI?

In the previous week, Xilio Therapeutics and Xilio Therapeutics both had 2 articles in the media. Dyadic International's average media sentiment score of 1.82 beat Xilio Therapeutics' score of 0.89 indicating that Dyadic International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xilio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts recommend DYAI or EXOZ?

Dyadic International presently has a consensus target price of $3.00, suggesting a potential upside of 589.34%. Given Dyadic International's stronger consensus rating and higher probable upside, research analysts clearly believe Dyadic International is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyadic International 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to IMA or DYAI?

In the previous week, ImageneBio and ImageneBio both had 2 articles in the media. Dyadic International's average media sentiment score of 1.82 beat ImageneBio's score of 0.91 indicating that Dyadic International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImageneBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor DYAI or ELTX?

In the previous week, Elicio Therapeutics had 5 more articles in the media than Dyadic International. MarketBeat recorded 7 mentions for Elicio Therapeutics and 2 mentions for Dyadic International. Dyadic International's average media sentiment score of 1.82 beat Elicio Therapeutics' score of 0.26 indicating that Dyadic International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Elicio Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Dyadic International (DYAI) Competitors

$0.44 +0.02 (+4.89%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$0.46 +0.02 (+5.24%)

As of 05:52 AM Eastern

Compare

DYAI vs. INKT, XLO, EXOZ, IMA, and ELTX

Should you buy Dyadic International stock or one of its competitors? Dyadic International's main competitors and comparable companies include MiNK Therapeutics (INKT), Xilio Therapeutics (XLO), eXoZymes (EXOZ), ImageneBio (IMA), and Elicio Therapeutics (ELTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Dyadic International compare to MiNK Therapeutics?

Dyadic International (NASDAQ:DYAI) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

Dyadic International presently has a consensus target price of $3.00, suggesting a potential upside of 589.34%. MiNK Therapeutics has a consensus target price of $35.00, suggesting a potential upside of 184.55%. Given Dyadic International's higher possible upside, equities research analysts plainly believe Dyadic International is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Dyadic International has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$1.33M	13.08	-$7.36M	-$0.23	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A

In the previous week, Dyadic International had 1 more articles in the media than MiNK Therapeutics. MarketBeat recorded 2 mentions for Dyadic International and 1 mentions for MiNK Therapeutics. Dyadic International's average media sentiment score of 1.82 beat MiNK Therapeutics' score of 1.79 indicating that Dyadic International is being referred to more favorably in the media.

Company	Overall Sentiment
Dyadic International	Very Positive
MiNK Therapeutics	Very Positive

Dyadic International has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market.

28.0% of Dyadic International shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 20.9% of Dyadic International shares are owned by insiders. Comparatively, 20.4% of MiNK Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

MiNK Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. MiNK Therapeutics' return on equity of 0.00% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-201.43%	-2,920.31%	-84.77%
MiNK Therapeutics	N/A	N/A	-92.37%

Summary

Dyadic International beats MiNK Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Dyadic International compare to Xilio Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and Dyadic International (NASDAQ:DYAI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Dyadic International has lower revenue, but higher earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.35	-$35.04M	-$1.64	N/A
Dyadic International	$1.33M	13.08	-$7.36M	-$0.23	N/A

In the previous week, Xilio Therapeutics and Xilio Therapeutics both had 2 articles in the media. Dyadic International's average media sentiment score of 1.82 beat Xilio Therapeutics' score of 0.89 indicating that Dyadic International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Xilio Therapeutics has a beta of -0.14, meaning that its stock price is 114% less volatile than the broader market. Comparatively, Dyadic International has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

Dyadic International has a consensus price target of $3.00, suggesting a potential upside of 589.34%. Given Dyadic International's stronger consensus rating and higher probable upside, analysts clearly believe Dyadic International is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Xilio Therapeutics has a net margin of -34.06% compared to Dyadic International's net margin of -201.43%. Xilio Therapeutics' return on equity of -71.99% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-34.06%	-71.99%	-20.43%
Dyadic International	-201.43%	-2,920.31%	-84.77%

54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 7.5% of Xilio Therapeutics shares are owned by insiders. Comparatively, 20.9% of Dyadic International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Dyadic International beats Xilio Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Dyadic International compare to eXoZymes?

Dyadic International (NASDAQ:DYAI) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

28.0% of Dyadic International shares are held by institutional investors. 20.9% of Dyadic International shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Dyadic International has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, eXoZymes has a beta of 3.14, indicating that its share price is 214% more volatile than the broader market.

eXoZymes has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. eXoZymes' return on equity of -292.15% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-201.43%	-2,920.31%	-84.77%
eXoZymes	N/A	-292.15%	-158.66%

In the previous week, Dyadic International had 1 more articles in the media than eXoZymes. MarketBeat recorded 2 mentions for Dyadic International and 1 mentions for eXoZymes. Dyadic International's average media sentiment score of 1.82 beat eXoZymes' score of 1.79 indicating that Dyadic International is being referred to more favorably in the media.

Company	Overall Sentiment
Dyadic International	Very Positive
eXoZymes	Very Positive

Dyadic International presently has a consensus target price of $3.00, suggesting a potential upside of 589.34%. Given Dyadic International's stronger consensus rating and higher probable upside, research analysts clearly believe Dyadic International is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Dyadic International has higher revenue and earnings than eXoZymes. eXoZymes is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$1.33M	13.08	-$7.36M	-$0.23	N/A
eXoZymes	$70K	840.50	-$9.16M	-$1.19	N/A

Summary

Dyadic International beats eXoZymes on 11 of the 16 factors compared between the two stocks.

How does Dyadic International compare to ImageneBio?

ImageneBio (NASDAQ:IMA) and Dyadic International (NASDAQ:DYAI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

ImageneBio has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market. Comparatively, Dyadic International has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

ImageneBio currently has a consensus price target of $29.00, suggesting a potential upside of 522.32%. Dyadic International has a consensus price target of $3.00, suggesting a potential upside of 589.34%. Given Dyadic International's higher possible upside, analysts plainly believe Dyadic International is more favorable than ImageneBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, ImageneBio and ImageneBio both had 2 articles in the media. Dyadic International's average media sentiment score of 1.82 beat ImageneBio's score of 0.91 indicating that Dyadic International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImageneBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Dyadic International has higher revenue and earnings than ImageneBio. Dyadic International is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	66.11	-$45.35M	-$4.58	N/A
Dyadic International	$1.33M	13.08	-$7.36M	-$0.23	N/A

75.0% of ImageneBio shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 2.2% of ImageneBio shares are held by insiders. Comparatively, 20.9% of Dyadic International shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ImageneBio has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. ImageneBio's return on equity of -38.99% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.99%	-34.84%
Dyadic International	-201.43%	-2,920.31%	-84.77%

Summary

ImageneBio beats Dyadic International on 8 of the 15 factors compared between the two stocks.

How does Dyadic International compare to Elicio Therapeutics?

Dyadic International (NASDAQ:DYAI) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

28.0% of Dyadic International shares are owned by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are owned by institutional investors. 20.9% of Dyadic International shares are owned by insiders. Comparatively, 50.9% of Elicio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Elicio Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. Elicio Therapeutics' return on equity of -1,266.43% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-201.43%	-2,920.31%	-84.77%
Elicio Therapeutics	N/A	-1,266.43%	-139.94%

Dyadic International currently has a consensus price target of $3.00, indicating a potential upside of 589.34%. Elicio Therapeutics has a consensus price target of $15.00, indicating a potential upside of 697.87%. Given Elicio Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Elicio Therapeutics is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Dyadic International has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market.

In the previous week, Elicio Therapeutics had 5 more articles in the media than Dyadic International. MarketBeat recorded 7 mentions for Elicio Therapeutics and 2 mentions for Dyadic International. Dyadic International's average media sentiment score of 1.82 beat Elicio Therapeutics' score of 0.26 indicating that Dyadic International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Elicio Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dyadic International has higher revenue and earnings than Elicio Therapeutics. Dyadic International is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$1.33M	13.08	-$7.36M	-$0.23	N/A
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A

Summary

Elicio Therapeutics beats Dyadic International on 10 of the 15 factors compared between the two stocks.

Get Dyadic International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DYAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DYAI vs. The Competition

Export

Metric	Dyadic International	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.62M	$3.97B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-1.89	14.00	274.39	25.76
Price / Sales	13.08	1,331.78	685.36	106.83
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	14.51	15.20	10.44	6.34
Net Income	-$7.36M	-$22.82M	$3.49B	$360.00M
7 Day Performance	4.87%	-1.99%	-0.95%	-0.18%
1 Month Performance	-37.02%	-8.15%	-4.24%	-4.09%
1 Year Performance	-62.80%	32.12%	16.39%	5.97%

Dyadic International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DYAI Dyadic International	2.8488 of 5 stars	$0.44 +4.9%	$3.00 +589.3%	-62.1%	$16.62M	$1.33M	N/A	5	News Coverage Positive News
INKT MiNK Therapeutics	3.1188 of 5 stars	$11.50 -4.0%	$35.00 +204.5%	-14.2%	$61.08M	N/A	N/A	30	Positive News
XLO Xilio Therapeutics	0.2839 of 5 stars	$9.03 +1.1%	N/A	-16.1%	$58.76M	$43.77M	N/A	70	High Trading Volume
EXOZ eXoZymes	1.0241 of 5 stars	$6.57 +4.6%	N/A	-56.6%	$58.29M	$70K	N/A	29	High Trading Volume
IMA ImageneBio	3.4022 of 5 stars	$4.92 -1.6%	$29.00 +489.4%	-41.8%	$56.76M	$800K	N/A	70

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DYAI) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dyadic International (DYAI) Competitors

DYAI vs. INKT, XLO, EXOZ, IMA, and ELTX

How does Dyadic International compare to MiNK Therapeutics?

Summary

How does Dyadic International compare to Xilio Therapeutics?

Summary

How does Dyadic International compare to eXoZymes?

Summary

How does Dyadic International compare to ImageneBio?

Summary

How does Dyadic International compare to Elicio Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI vs. The Competition

Dyadic International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dyadic International (DYAI) Competitors

DYAI vs. INKT, XLO, EXOZ, IMA, and ELTX

How does Dyadic International compare to MiNK Therapeutics?

Do analysts prefer DYAI or INKT?

Which has better valuation and earnings, DYAI or INKT?

Does the media refer more to DYAI or INKT?

Which has more volatility and risk, DYAI or INKT?

Do institutionals & insiders hold more shares of DYAI or INKT?

Is DYAI or INKT more profitable?

Summary

How does Dyadic International compare to Xilio Therapeutics?

Which has higher earnings & valuation, XLO or DYAI?

Does the media refer more to XLO or DYAI?

Which has more risk & volatility, XLO or DYAI?

Do analysts rate XLO or DYAI?

Is XLO or DYAI more profitable?

Do insiders & institutionals hold more shares of XLO or DYAI?

Summary

How does Dyadic International compare to eXoZymes?

Do insiders and institutionals hold more shares of DYAI or EXOZ?

Which has more risk & volatility, DYAI or EXOZ?

Is DYAI or EXOZ more profitable?

Does the media refer more to DYAI or EXOZ?

Do analysts recommend DYAI or EXOZ?

Which has higher valuation and earnings, DYAI or EXOZ?

Summary

How does Dyadic International compare to ImageneBio?

Which has more volatility & risk, IMA or DYAI?

Do analysts recommend IMA or DYAI?

Does the media refer more to IMA or DYAI?

Which has preferable earnings & valuation, IMA or DYAI?

Do institutionals & insiders hold more shares of IMA or DYAI?

Is IMA or DYAI more profitable?

Summary

How does Dyadic International compare to Elicio Therapeutics?

Do institutionals and insiders have more ownership in DYAI or ELTX?

Is DYAI or ELTX more profitable?

Do analysts prefer DYAI or ELTX?

Which has more volatility and risk, DYAI or ELTX?

Does the media favor DYAI or ELTX?

Which has preferable earnings & valuation, DYAI or ELTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI vs. The Competition

Dyadic International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools